BB's Stock Haven

[HokieHead]

NNLX +100%, in a hostile takeover battle...

with Nutra Pharma (+53% today). NanoLogix says:

-NanoLogix management secured a fairness opinion and analysis from an independent CPA firm and the Company's general counsel. The conclusion reached by both parties suggests that Nutra Pharma's demands would be grossly unfair to the Company and to its shareholders. In particular, noted the analysis, "the consideration offered by Nutra Pharma is not commensurate with what we believe the current fair market value of the intellectual property to be with respect to perceived and potential future value."

-CEO of NanoLogix, Dr. Mitch Felder, commented, "Nutra Pharma is all too aware of the real potential economic value of NanoLogix's patent portfolio. While we want to continue our relationship with Nutra Pharma, we are not willing to release the principal assets of NanoLogix for anything less than fair value. Nutra Pharma's demands are clearly not in the best interest of the company and its shareholders. If Nutra Pharma were to agree to reasonable terms, we would consider a transfer of our intellectual property."

-Randall S. Goulding, NanoLogix's General Counsel stated, "Effectively, what Nutra Pharma was trying to do is to acquire all of the assets of NanoLogix at a fraction of their intrinsic value. Their 'offer,' if that is what you want to call it, is grossly unfair, egregious and is overreaching." He continued, "Recognizing the inherent value of the patent portfolio, we have introduced the Company to various strategic investors to assure that the Bioreactor Facility will be constructed pursuant to the agreement with Welch's as well as to provide funding to bring to market and monetize the remainder of the Company's patent portfolio."


NNLX gonna fly north of $1 imo.


NanoLogix, Inc. (IFEC) NanoLogix, Inc., formerly known as InfectTech, Inc., is a technology application innovator of biogas products and services designed to assist in worldwide energy independence and reduce pollution from renewable, environmentally-friendly energy sources. NanoLogix is also engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious human diseases. The Company's patents span the identification and antibiotic sensitivity testing of 34 disease-producing bacteria, including M. tuberculosis (TB), Mycobacterium avium-intracellulare (MAI), pseudomonas, and nocardia. These bacteria are cited as prominent causes of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS. Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for inducing a genetically based induction of "cell suicide" in cells.